{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:34Z","timestamp":1792176394187,"version":"4.4.0"},"reference-count":60,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objective\u2003Our objective was to compare fetal growth and incidence of neonatal abstinence syndrome requiring treatment across pregnant women with opioid use disorders on two types and two dose categories of medication-assisted treatment.<\/jats:p>\n                  <jats:p>Study Design\u2003A retrospective cohort study was conducted in a comprehensive, perinatal program in western North Carolina comparing growth percentiles on third-trimester ultrasound and at birth, and diagnosis of neonatal abstinence syndrome requiring treatment. Singletons were exposed in utero to low- to moderate-dose buprenorphine (\u226416\u2009mg\/day; n\u2009=\u200970), high-dose buprenorphine (\u226517\u2009mg\/day; n\u2009=\u200936), low- to moderate-dose methadone (\u226489\u2009mg\/day; n\u2009=\u200941), or high-dose methadone (\u226590\u2009mg\/day; n\u2009=\u200974). Multivariate analysis of variance with posthoc Bonferroni comparisons (p \u2264\u20090.01) and multinomial logistic regressions (adjusted odds ratio, 99% confidence interval) were conducted.<\/jats:p>\n                  <jats:p>Results\u2003Differences in neonatal outcomes reached statistical significance for larger head circumference for buprenorphine doses (p\u2009=\u20090.01) and for longer length (p\u2009&lt;\u20090.01) and lower odds of neonatal abstinence syndrome requiring treatment (p\u2009&lt;\u20090.01) with low- to moderate-dose buprenorphine versus high-dose methadone.<\/jats:p>\n                  <jats:p>Conclusion\u2003Among pregnant women using medication-assisted treatment for opioid use disorders, low- to moderate-dose buprenorphine (\u226416\u2009mg\/day) was associated with the most favorable neonatal outcomes. However, more rigorous control of confounders with a larger sample is necessary to determine if low- to moderate-dose buprenorphine is the better treatment choice.<\/jats:p>","DOI":"10.1055\/s-0039-1694729","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T18:34:20Z","timestamp":1566066860000},"page":"028-036","source":"Crossref","is-referenced-by-count":12,"title":["Association of Maternal Buprenorphine or Methadone Dose with Fetal Growth Indices and Neonatal Abstinence Syndrome"],"prefix":"10.1055","volume":"38","author":[{"given":"Carol C.","family":"Coulson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mountain Area Health Education Center, Asheville, North Carolina"},{"name":"Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Lorencz","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mountain Area Health Education Center, Asheville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Rittenhouse","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine\u2014Asheville, Asheville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Ramage","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mountain Area Health Education Center, Asheville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mountain Area Health Education Center, Asheville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley L.","family":"Galvin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mountain Area Health Education Center, Asheville, North Carolina"},{"name":"Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2019,8,17]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/11632820-000000000-00000","article-title":"Methadone and buprenorphine for the management of opioid dependence in pregnancy","volume":"72","author":"H E Jones","year":"2012","journal-title":"Drugs"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/AOG.0000000000002054","article-title":"Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation","volume":"130","author":"U M Reddy","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"12","key":"ref3","first-page":"CD006318","article-title":"Maintenance agonist treatments for opiate-dependent pregnant women","volume":"12","author":"S Minozzi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy","volume":"130","author":"Committee on Obstetric Practice","year":"2017","journal-title":"Obstet Gynecol"},{"key":"ref5","volume-title":"Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/FTD.0b013e3181d0bd68","article-title":"Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes","volume":"32","author":"M Concheiro","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"64.e1","DOI":"10.1016\/j.ajog.2016.09.095","article-title":"Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy","volume":"216","author":"J R Bastian","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/aje\/kwu190","article-title":"Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis","volume":"180","author":"S B Brogly","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/add.13462","article-title":"Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child","volume":"111","author":"B K Zedler","year":"2016","journal-title":"Addiction"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0034-1374817","article-title":"Chronic opiate use in pregnancy and newborn head circumference","volume":"32","author":"K C Visconti","year":"2015","journal-title":"Am J Perinatol"},{"issue":"S 01","key":"ref11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1360-0443.2012.04035.x","article-title":"Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review","volume":"107","author":"H E Jones","year":"2012","journal-title":"Addiction"},{"issue":"24","key":"ref12","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"H E Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"S 02","key":"ref13","first-page":"5","article-title":"Birth and neonatal outcomes following opioid use in pregnancy: a Danish population-based study","volume":"9","author":"M N\u00f8rgaard","year":"2015","journal-title":"Subst Abuse"},{"key":"ref14","first-page":"89","article-title":"A Swedish population-based study of adverse birth outcomes among pregnant women treated with buprenorphine or methadone: preliminary findings","volume":"10","author":"K E Wurst","year":"2016","journal-title":"Subst Abuse"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/AOG.0000000000000640","article-title":"Buprenorphine and naloxone compared with methadone treatment in pregnancy","volume":"125","author":"S L Wiegand","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"F258","DOI":"10.1136\/adc.2009.163105","article-title":"Growth restriction in pregnancies of opioid-dependent mothers","volume":"95","author":"A JW Liu","year":"2010","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000210042","article-title":"Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study","volume":"15","author":"B Bakstad","year":"2009","journal-title":"Eur Addict Res"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1479-828X.2011.01342.x","article-title":"The relationship between maternal opiate use, amphetamine use and smoking on fetal growth","volume":"51","author":"C Delsing","year":"2011","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ntt.2013.05.003","article-title":"The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations","volume":"39","author":"H E Jones","year":"2013","journal-title":"Neurotoxicol Teratol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.drugalcdep.2013.11.006","article-title":"Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy","volume":"134","author":"H E Jones","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2012.07.001","article-title":"Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009","volume":"127","author":"G K Welle-Strand","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamapsychiatry.2017.2733","article-title":"Association of panic disorder, generalized anxiety disorders, and benzodiazepine treatment during pregnancy with risk of adverse birth outcomes","volume":"74","author":"K A Yonkers","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"j3326","DOI":"10.1136\/bmj.j3326","article-title":"Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study","volume":"358","author":"K F Huybrechts","year":"2017","journal-title":"BMJ"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/add.12078","article-title":"Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women","volume":"108","author":"B J Cleary","year":"2013","journal-title":"Addiction"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/14767058.2014.987750","article-title":"Does concurrent in utero exposure to buprenorphine and antidepressant medications influence the course of neonatal abstinence syndrome?","volume":"29","author":"A B O'Connor","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1360-0443.2010.03120.x","article-title":"Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis","volume":"105","author":"B J Cleary","year":"2010","journal-title":"Addiction"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/14767058.2015.1018168","article-title":"The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment","volume":"29","author":"C Kreitinger","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jpeds.2010.03.033","article-title":"Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome","volume":"157","author":"N S Seligman","year":"2010","journal-title":"J Pediatr"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jpeds.2010.08.047","article-title":"Maternal methadone dose at delivery and neonatal abstinence syndrome","volume":"157","author":"A J Liu","year":"2010","journal-title":"J Pediatr"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1479-828X.2010.01168.x","article-title":"Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy","volume":"50","author":"A J Liu","year":"2010","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ntt.2010.01.007","article-title":"Maternal methadone dose during pregnancy and infant clinical outcome","volume":"32","author":"T A Wouldes","year":"2010","journal-title":"Neurotoxicol Teratol"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"139.e1","DOI":"10.1016\/j.ajog.2010.10.004","article-title":"Methadone and perinatal outcomes: a retrospective cohort study","volume":"204","author":"B J Cleary","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/hup.1224","article-title":"Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women","volume":"26","author":"V Metz","year":"2011","journal-title":"Hum Psychopharmacol"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jsat.2010.11.007","article-title":"Higher maternal doses of methadone does not increase neonatal abstinence syndrome","volume":"40","author":"D Pizarro","year":"2011","journal-title":"J Subst Abuse Treat"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/jp.2010.66","article-title":"Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome","volume":"31","author":"B Isemann","year":"2011","journal-title":"J Perinatol"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/jp.2015.22","article-title":"Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine","volume":"35","author":"J B Bier","year":"2015","journal-title":"J Perinatol"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/ADM.0000000000000099","article-title":"The effect of methadone dose regimen on neonatal abstinence syndrome","volume":"9","author":"J J McCarthy","year":"2015","journal-title":"J Addict Med"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000441220","article-title":"Maternal buprenorphine dose at delivery and its relationship to neonatal outcomes","volume":"22","author":"A B O'Connor","year":"2016","journal-title":"Eur Addict Res"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"529.e1","DOI":"10.1016\/j.ajog.2017.01.040","article-title":"Maternal buprenorphine treatment and fetal neurobehavioral development","volume":"216","author":"L M Jansson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/FTD.0b013e31822724f0","article-title":"Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes","volume":"33","author":"A de Castro","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1373\/clinchem.2010.154864","article-title":"Maternal methadone dose, placental methadone concentrations, and neonatal outcomes","volume":"57","author":"A de Castro","year":"2011","journal-title":"Clin Chem"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jat\/34.8.498","article-title":"Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes","volume":"34","author":"M Concheiro","year":"2010","journal-title":"J Anal Toxicol"},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/clpt.2008.156","article-title":"Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes","volume":"84","author":"S L Kacinko","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.earlhumdev.2017.11.009","article-title":"Prenatal buprenorphine exposure and neonatal neurobehavioral functioning","volume":"117","author":"M L Velez","year":"2018","journal-title":"Early Hum Dev"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.ajog.2017.06.029","article-title":"An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy","volume":"217","author":"S N Caritis","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ntt.2013.02.004","article-title":"Response to Wouldes and Woodward: maternal methadone dose during pregnancy and infant clinical outcome","volume":"39","author":"K E O'Grady","year":"2013","journal-title":"Neurotoxicol Teratol"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/AOG.0000000000002054","article-title":"Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation","volume":"130","author":"U M Reddy","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/AOG.0000000000001446","article-title":"Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic","volume":"128","author":"E E Krans","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/AOG.0000000000002046","article-title":"Committee Opinion No. 700: methods for estimating the due date","volume":"129","author":"Committee on Obstetric Practice, the American Institute of Ultrasound in Medicine, and the Society for Maternal-Fetal Medicine","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5055\/jom.2009.0006","article-title":"The opioid-exposed newborn: assessment and pharmacologic management","volume":"5","author":"L M Jansson","year":"2009","journal-title":"J Opioid Manag"},{"key":"ref52","volume-title":"Pharmacology","author":"Substance Abuse and Mental Health Services Administration","year":"2004"},{"issue":"09","key":"ref53","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00228-017-2269-4","article-title":"The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies","volume":"73","author":"C R Tak","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"ref54","volume-title":"Substance Abuse Treatment for Persons with Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series No. 42","author":"Substance Abuse and Mental Health Services Administration","year":"2005"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1542\/peds.2011-3212","article-title":"Neonatal drug withdrawal","volume":"129","author":"M L Hudak","year":"2012","journal-title":"Pediatrics"},{"issue":"S 01","key":"ref56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1360-0443.2012.04038.x","article-title":"Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication","volume":"107","author":"K Kaltenbach","year":"2012","journal-title":"Addiction"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/ADM.0b013e3182266a3a","article-title":"The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome","volume":"5","author":"E M Wachman","year":"2011","journal-title":"J Addict Med"},{"issue":"10","key":"ref58","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1080\/14767058.2017.1414180","article-title":"Nonpharmacological management of neonatal abstinence syndrome: a review of the literature","volume":"32","author":"G Ryan","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(14)61277-0","article-title":"Effects of perinatal mental disorders on the fetus and child","volume":"384","author":"A Stein","year":"2014","journal-title":"Lancet"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"e1393","DOI":"10.1542\/peds.2014-3172","article-title":"Head growth and neurocognitive outcomes","volume":"135","author":"C M Wright","year":"2015","journal-title":"Pediatrics"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"661.e1","DOI":"10.1016\/j.ajog.2014.12.001","article-title":"Prenatal head growth and child neuropsychological development at age 14\u2009months","volume":"212","author":"D \u00c1lamo-Junquera","year":"2015","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0039-1694729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:16:14Z","timestamp":1721607374000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0039-1694729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,17]]},"references-count":60,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2020,12,29]]},"published-print":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0039-1694729","relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,17]]}}}